Gene Editing Has the Science Figured Out and Now Needs an Entire Stack of New Business Models, Reimbursement Mechanics, and Healthcare Operating Infrastructure Before Any of This Scales to Patients
Quick Links: Knowledge Base, Podcast, and Social
Knowledge Base — search and filter every article and podcast episode by topic, section, and keyword: kb.onhealthcare.tech
Listen to the Podcast — every article is also available as an audio episode. Free subscribers get the public episodes; paid subscribers get the full archive including subscriber-only episodes. Listen on Apple Podcasts, Spotify, or browse all episodes on the Substack Podcast page.
For paid subscribers — your subscription unlocks the entire research archive (538+ deep-dives), every paid podcast episode, and full search inside the Knowledge Base. To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
For free subscribers — free posts and free podcast episodes are always public on Apple/Spotify and Substack. Upgrade any time at onhealthcare.tech/subscribe to access the paid archive and paid episodes.
Follow on Social — X · YouTube · TikTok · Instagram
Video Preview
Podcast
Table of Contents
Abstract
The CASGEVY tell
Why a one-time cure breaks the operating system
The diagnosis problem nobody wants to fund
Outcomes-based contracting and the Medicaid math
Treatment centers as managed service lines
Off-target analytics becomes a regulated lab category
CMC comparability is now a strategy job
Editor foundries and the semiconductor analogy
Registries that payers, regulators, and reinsurers actually trust
Reinsurance and stop-loss for curative therapies
Trial operations for genetically segmented populations
The punchline
Q1 2026 CASGEVY revenue was about $43M (Vertex), with 500+ patient initiations globally since launch. CMS lists CASGEVY at $2.2M. Pediatric expansion (ages 5 to under 12) submission is filed in the U.S., and a Germany pricing agreement is in place.
Beam reported $1.2B cash, runway into mid-2029, BEAM-302 dose selected at 60 mg, pivotal cohort planned in H2 2026, risto-cel BLA possibly by year-end 2026, BEACON Phase 1/2 data published in NEJM.
Intellia announced positive Phase 3 HAELO data for lonvo-z in HAE on April 27, 2026, with rolling BLA underway and possible launch H1 2027 if approved.
Prime Medicine plans IND/CTA for PM577 (Wilson disease) in H1 2026 and PM647 (AATD) around mid-2026, initial clinical data 2027.
FDA issued April 2026 draft guidance on safety assessment of genome editing using NGS, applicable to ex vivo and in vivo products. ASGCT Q1 2026 landscape report counted only two new approvals globally in the quarter, both non-genetically modified cell therapies.
Thesis: the bottleneck is no longer scientific. It is operational, financial, and regulatory. The next cycle of returns belongs to infrastructure companies (activation, contracting, orchestration, registry, reinsurance, foundry, regulated NGS lab) at least as much as to editor platforms.
The CASGEVY tell
Pretty much everything anyone needs to know about where gene editing is right now lives inside two facts from Vertex’s Q1 2026 release. CASGEVY did about $43 million of revenue. More than 500 patients have started the treatment journey since launch. Both numbers can be read two completely different ways depending on what story is being told that day. If the story is “CRISPR works as a commercial product,” then $43 million in a quarter is meaningful for a one-time, ultra-rare, infused cell therapy whose treatment journey is measured in months. If the story is “approved gene editing scales easily through normal pharma channels,” then $43 million on a $2.2 million list price is, charitably, a reminder that the slope of adoption is going to look nothing like a small molecule launch and probably not even like a typical biologic.
The reason the slope is weird is the part that almost nobody outside the actual transplant centers fully understands. CASGEVY is not really a drug. It is a multi-month coordinated services bundle that happens to include a drug substance somewhere in the middle. A patient gets identified, gets screened against clinical and psychosocial eligibility, gets offered fertility preservation, has cells mobilized and apheresed, ships those cells to a manufacturing site, waits for editing and release testing, gets conditioned with busulfan, gets infused, sits inpatient for engraftment, then enters years of follow-up. Most of that is not a Vertex problem. Most of that is a hospital problem, a Medicaid problem, a fertility clinic problem, a benefit design problem, and a workforce problem. Anyone trying to underwrite the future of gene editing without understanding that breakdown is basically valuing the engine without checking if the rest of the car exists.
CRISPR Therapeutics’ own Q1 release captured the same dynamic from the partner side. Roughly 60,000 eligible patients across approved geographies, the same 500-plus initiations, an active push into pediatric expansion, the Germany pricing deal, and a continued profit-share with Vertex on the launch. That is encouraging activity for one quarter, and it is also a flashing yellow light on the gap between approved and treated. Demand exists. Capacity is the bottleneck. And capacity is not something that gets fixed with another R&D dollar.
Why a one-time cure breaks the operating system
